GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Isleworth Healthcare Acquisition Corp (NAS:ISLEW) » Definitions » Common Stock

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Common Stock : $207.16 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Isleworth Healthcare Acquisition Common Stock?

Isleworth Healthcare Acquisition's quarterly common stock stayed the same from Dec. 2021 ($207.00 Mil) to Mar. 2022 ($207.00 Mil) but then increased from Mar. 2022 ($207.00 Mil) to Jun. 2022 ($207.16 Mil).

Isleworth Healthcare Acquisition's annual common stock increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) and increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($207.00 Mil).

Isleworth Healthcare Acquisition Common Stock Historical Data

The historical data trend for Isleworth Healthcare Acquisition's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isleworth Healthcare Acquisition Common Stock Chart

Isleworth Healthcare Acquisition Annual Data
Trend Dec20 Dec21
Common Stock
- 207.00

Isleworth Healthcare Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Common Stock Get a 7-Day Free Trial 191.04 207.00 207.00 207.00 207.16

Isleworth Healthcare Acquisition Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Isleworth Healthcare Acquisition Corp (NAS:ISLEW) » Definitions » Common Stock
Comparable Companies
AVAC TRCA IFIN WAVC IQMD FRW SHCA OCA BIOT DWIN GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
360 Central Avenue, First Central Tower, Suite No. 800, Saint Petersburg, FL, USA, 33701
Website
https://www.isleworthhealthcare.com
Isleworth Healthcare Acquisition Corp is a blank check company.

Isleworth Healthcare Acquisition (Isleworth Healthcare Acquisition) Headlines

From GuruFocus

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 05-16-2022

Isleworth Healthcare Acquisition Corp. Announces Closing of $207,000,000 Initial Public Offering, Including Full Exercise of Underwriter Over-Allotment Option

By PRNewswire PRNewswire • 03-03-2021

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 05-26-2022

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK� Cell Engager at EHA 2022 Congress

By PRNewswire PRNewswire • 07-07-2022

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 07-10-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 07-05-2022

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK� Cell Engager at EHA 2022 Congress

By PRNewswire PRNewswire • 05-28-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 06-05-2022

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 06-10-2022

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 06-30-2022